Exagen Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Wed, August 5, 2026 at 12:23 AM GMT+3 3 min read

Exagen Inc. Q2 2026 Earnings Call Summary - Moby

Strategic Performance Drivers

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Achieved record quarterly revenue of $19.9 million, driven by a 16% year-over-year increase and record AVISE test volumes.
Successfully rebuilt the volume base on a stronger economic foundation, with trailing 12-month ASP nearly 40% higher than 2023 levels following a deliberate commercial reset.
Expanded trailing 12-month ASP to $446, marking the 13th consecutive quarter of growth through disciplined revenue cycle management and commercial payer appeals.
Leveraged analytics and AI within the revenue cycle team to automate appeals and streamline medical record extraction, contributing to improved collections.
Pharma services revenue crossed the $1 million quarterly threshold for the first time, validating the company's unique data and biobank capabilities for drug developers.
Published a systematic review showing AVISE Lupus identified approximately 25% of SLE patients missed by conventional markers, strengthening the clinical evidence base.
Sales force productivity reached record levels of $1.4 million per territory, reflecting successful training and the 10% expansion executed in late 2025.

Outlook and Strategic Roadmap

Raised full-year 2026 revenue guidance to $72 million to $75 million, assuming high single-digit volume growth and mid-single-digit ASP growth.
Anticipates reaching sustainable adjusted EBITDA breakeven at approximately $80 million in annual revenue, supported by inherent operating leverage.
Commercialization of the new myositis stand-alone product remains on track for early 2027, with a goal of launching one new product every 12 months thereafter.
Targets a long-term ASP of $600 to $650 per test, representing at least 50% of Medicare reimbursement, though timing remains variable.
Guidance incorporates typical second-half seasonality, accounting for fewer working days and physician vacation patterns compared to the first half.

Operational and Financial Risks

Collected over $1 million from claims older than 360 days in Q2, highlighting the variability and impact of prior-period recoveries on current results.
Operating expenses grew only 7% despite 16% revenue growth, demonstrating cost discipline even as R&D investments for the pipeline continue.
Medicare reimbursement remains stable, but the timing for an updated Local Coverage Determination (LCD) from MolDX remains opaque and outside company control.
Cash and accounts receivable of $37 million are deemed sufficient to reach sustainable profitability without requiring additional capital.

Q&A Session Summary

Conservatism in second half guidance and seasonality factors

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management noted that while 2025 saw an atypical lack of seasonality, they are assuming a return to historical patterns with fewer working days in Q4.
The $2 million guidance raise reflects first-half outperformance while remaining cautious about the 'reality' of second-half holiday impacts.

Contribution of new biomarkers to ASP growth

New biomarkers (T-Cell, RA33, and PAD4) are currently tracking in the mid-$90 range per test, close to the long-term target of $100.
ASP growth is currently driven by a blend of these new markers and improved collections from private payers through the appeals process.

Sales force strategy for upcoming myositis product launch

The existing 45-territory sales force will sell the myositis test concurrently with AVISE CTD, as the clinician call point is identical.
Management will evaluate further sales force expansion only after the 2027 launch once initial uptake and territory potential are assessed.

Path to sustained EBITDA positivity and investment risks

While Q2 was near breakeven, management cautioned that seasonality and upcoming product launch investments might cause fluctuations in the second half.
The primary risks to the profitability timeline include reimbursement shifts and potential volume hits from key clients, though neither is currently foreseen.